IBI 324
Alternative Names: IBI-324Latest Information Update: 07 Nov 2023
At a glance
- Originator Innovent Biologics
- Class Anti-inflammatories; Bispecific antibodies; Eye disorder therapies; Recombinant fusion proteins
- Mechanism of Action Angiopoietin-2 inhibitors; Vascular endothelial growth factor A inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Diabetic macular oedema
Most Recent Events
- 06 Nov 2023 Efficacy and adverse event data from a phase I trial in Age-related macular degeneration released by Innovent Biologics
- 05 Jun 2023 Innovent Biologics completes a phase I trial in Diabetic macular edema in China (NCT05489718)
- 07 Aug 2022 Phase-I clinical trials in Diabetic macular oedema (In adults, In the elderly) in China (Intravitreous) (9365051; NCT05489718)